Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.
Original language | English |
---|---|
Pages (from-to) | 239-256 |
Number of pages | 18 |
Journal | Diabetes Therapy |
Volume | 6 |
Issue number | 3 |
DOIs | |
Publication status | Published - Sep 26 2015 |
Keywords
- GLP-1 RAs
- Glucagon-like peptide-1 receptor agonists
- Incretin
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine